| Identification | Back Directory | [Name]
3H-Imidazo[4,5-b]pyridine-6-carboxamide, 3-[(2E)-4-[5-(aminocarbonyl)-2-[[(4-ethyl-2-methyl-5-oxazolyl)carbonyl]amino]-7-(3-hydroxypropoxy)-1H-benzimidazol-1-yl]-2-buten-1-yl]-2-[[(4-ethyl-2-methyl-5-oxazolyl)carbonyl]amino]- | [CAS]
2591300-72-8 | [Synonyms]
STING agonist-20
3H-Imidazo[4,5-b]pyridine-6-carboxamide, 3-[(2E)-4-[5-(aminocarbonyl)-2-[[(4-ethyl-2-methyl-5-oxazolyl)carbonyl]amino]-7-(3-hydroxypropoxy)-1H-benzimidazol-1-yl]-2-buten-1-yl]-2-[[(4-ethyl-2-methyl-5-oxazolyl)carbonyl]amino]- | [Molecular Formula]
C36H39N11O8 | [MOL File]
2591300-72-8.mol | [Molecular Weight]
753.76 |
| Hazard Information | Back Directory | [Uses]
STING agonist-20 (compound 95) is a potent STING agonist used in the synthesis of XMT-2056. STING agonist-20 can be used as a vaccine adjuvant in the study of cancer and other inflammatory, immune diseases[1]. | [References]
[1] R. DUVALL J, et al., Sting agonist compounds and methods of use. US20210032269 |
|
| Company Name: |
Biorbyt Ltd.
|
| Tel: |
+44 (0)1223 859 353 |
| Website: |
http://www.biorbyt.com |
|